Skip to content

Sutro Biopharma STRO Price / sales

Price / sales at other companies

Pfizer logo
PfizerPFE
2.5×+0.2×
Gilead Sciences logo
Gilead SciencesGILD
5.8×+1.0×
Regenxbio logo
RegenxbioRGNX
4.9×+2.6×
Xencor logo
XencorXNCR
9.1×+3.2×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
6.9×+1.8×
Schrodinger logo
SchrodingerSDGR
3.3×-3.0×

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Calculated from Sutro Biopharma’s reported figures.

Based on the most recent quarter.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's price / sales?
Sutro Biopharma (STRO) reported price / sales of 4.1× in Q1 2026.
How has Sutro Biopharma's price / sales changed year-over-year?
Sutro Biopharma's price / sales increased by 405.0% year-over-year, from 0.8× to 4.1×.
What is the long-term trend for Sutro Biopharma's price / sales?
Over 5 years (2020 to 2025), Sutro Biopharma's price / sales has grown at a -47.2% compound annual growth rate (CAGR), from 23.5× to 1×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.